The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | Findings from AML18: MRD as an endpoint and treatment intensification based on MRD status
Sylvie Freeman, MBChB, MRCP, DPhil, FRCPath, University of Birmingham, Birmingham, UK, shares findings from the AML18 trial (NCT02272478), a UK-based study in fit older adults with acute myeloid leukemia (AML). The findings supported the use of measurable residual disease (MRD) as a surrogate endpoint in AML, and demonstrated that intensification of chemotherapy in those who were MRD negative reduced relapse and increased survival. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the AML18 trial, which is led by Nigel Russell, is a UK trial and that was in fit older adults. And it’s investigated several things. First of all, we had several induction randomizations and we could show that the benefit of the investigational arm compared to the control arm could be detected early by flow MRD after course one. So that gives hope for MRD as a surrogate endpoint in AML...
So the AML18 trial, which is led by Nigel Russell, is a UK trial and that was in fit older adults. And it’s investigated several things. First of all, we had several induction randomizations and we could show that the benefit of the investigational arm compared to the control arm could be detected early by flow MRD after course one. So that gives hope for MRD as a surrogate endpoint in AML. Obviously, there’s a journey to go for that, but it gives hope. The other very important finding is that previously it’s been shown that if a patient has MRD positivity, then allogeneic transplant, if the patient is well or fit enough, can at least partially overcome the bad of that MRD positivity. We’ve not known yet whether actually intensifying chemotherapy early on can also provide benefits. So in AML18, we randomised patients between continuing with standard chemotherapy or having intensification treatment. And the intensification treatment reduced relapse and increased survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
